Price Don’t Lie: Could AMAG Pharmaceuticals, Inc. Change Direction After Today’s Big Increase?

Price Don't Lie: Could AMAG Pharmaceuticals, Inc. Change Direction After Today's Big Increase?

The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a huge mover today! The stock increased 6.76% or $2.1 on November 23, hitting $33.15. About 1.06M shares traded hands or 21.12% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 14.67% since April 22, 2016 and is uptrending. It has outperformed by 9.26% the S&P500.
The move comes after 9 months positive chart setup for the $1.11 billion company. It was reported on Nov, 24 by Barchart.com. We have $35.14 PT which if reached, will make NASDAQ:AMAG worth $66.60 million more.

Analysts await AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report earnings on February, 15. They expect $0.27 EPS, up 35.00% or $0.07 from last year’s $0.2 per share. AMAG’s profit will be $9.04 million for 30.69 P/E if the $0.27 EPS becomes a reality. After $0.43 actual EPS reported by AMAG Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -37.21% negative EPS growth.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Out of 6 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. AMAG Pharmaceuticals has been the topic of 16 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The rating was maintained by Deutsche Bank on Wednesday, November 4 with “Hold”. The firm has “Strong-Buy” rating by Zacks given on Wednesday, August 19. Needham initiated it with “Buy” rating and $40 target price in Thursday, October 27 report. The rating was initiated by Raymond James with “Outperform” on Tuesday, September 1. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Market Perform” rating by Raymond James on Wednesday, May 4. On Thursday, November 19 the stock rating was maintained by Deutsche Bank with “Hold”. The rating was reinitiated by Deutsche Bank on Thursday, September 3 with “Hold”. The company was initiated on Tuesday, August 18 by Jefferies. The firm has “Buy” rating given on Thursday, August 11 by Jefferies. Barclays Capital initiated AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Thursday, January 21 with “Equal-Weight” rating.

According to Zacks Investment Research, “AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex®, the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.”

Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.24, from 0.83 in 2016Q1. The ratio increased, as 33 funds sold all AMAG Pharmaceuticals, Inc. shares owned while 51 reduced positions. 15 funds bought stakes while 55 increased positions. They now own 42.73 million shares or 1.35% more from 42.16 million shares in 2016Q1.
Kcg Holding, a New Jersey-based fund reported 12,327 shares. Fmr Llc holds 0.01% or 4.15M shares in its portfolio. Thrivent Financial For Lutherans reported 16,940 shares or 0% of all its holdings. Springbok Cap Mngmt Limited Company owns 11,409 shares or 0.04% of their US portfolio. Prudential Financial Incorporated accumulated 442,877 shares or 0.02% of the stock. Teachers Advsr holds 55,547 shares or 0% of its portfolio. Morgan Stanley has 975,575 shares for 0.01% of their US portfolio. Opaleye Mgmt has 1.3% invested in the company for 295,000 shares. Ubs Asset Mngmt Americas Incorporated has invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Loomis Sayles L P accumulated 190 shares or 0% of the stock. Proshare Advsr Lc last reported 0.01% of its portfolio in the stock. Acadian Asset Mgmt last reported 3,743 shares in the company. Louisiana State Employees Retirement Sys holds 0.02% or 15,300 shares in its portfolio. The California-based Blackrock Institutional Trust Communication Na has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Signalpoint Asset Mngmt Ltd Liability Corporation holds 0.2% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 20,055 shares.

Insider Transactions: Since October 20, 2016, the stock had 0 insider buys, and 1 insider sale for $122,462 net activity. On Thursday, October 20 Krop Julie sold $122,462 worth of the stock or 4,938 shares.

AMAG Company Profile

AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Firm has a portfolio of services and products with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment